Summary of Tenon Medical (TNON) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Q2 revenue reached $1.3 million, a 127% increase year-over-year, marking the highest second-quarter revenue in the company's history. For the first half of 2026, revenue was $2.7 million, up 106% from $1.3 million in the same period of 2025.

Gross Profit: Q2 gross profit was $800,000 (64% margin), up 232% year-over-year. For the first half, gross profit was $1.8 million (66% margin), a 210% increase from $600,000 in H1 2025.

Operating Loss: The loss from operations for the first half was $6.6 million, slightly higher than the $6.5 million loss in the previous year. Q2 net loss was $4.1 million ($12.35 per share), compared to a net loss of $2.8 million ($12.76 per share) in Q2 2025.

Cash Position: Cash and cash equivalents at the end of Q2 were $1.7 million, down from $3.8 million at the end of 2025. A public offering on July 1 raised $4.2 million in gross proceeds.

2Strategic Updates and Business Highlights

Product Development: The company received FDA 510(k) clearance for the Catamaran SI joint fusion system, which includes upgrades that are expected to enhance performance and reduce costs.

Sales and Training Expansion: Significant growth in physician and distributor training was noted, with a 98% increase in training events in the first half of 2026 compared to the second half of 2025. The newly opened Tampa sales and training office has driven increased engagement.

R&D Initiatives: Upcoming product launches include an enhanced SImmetry+ system and a novel posterior approach technology, with expected FDA submissions in the near future.

3Forward Guidance and Outlook

The company aims to continue growing procedure volumes, expand physician training, and accelerate key R&D projects. Management is optimistic about maintaining gross margin improvements as they scale operations and expects to leverage their enhanced product offerings to capture market share.

4Bad News, Challenges, or Points of Concern

Operating Losses: Despite revenue growth, operating losses remain substantial, with a net loss increase attributed to non-cash interest expenses related to convertible notes.

Cash Burn: The significant decrease in cash reserves raises concerns about liquidity, although the recent capital raise provides some relief.

Seasonality in Training: There is potential seasonality affecting physician training activities, which could impact growth momentum in the latter half of the year.

5Notable Q&A Insights

SiVantage Product Pipeline: Management expressed confidence in the SiVantage product pipeline, highlighting advancements and upcoming regulatory submissions.

Training Initiatives: The new Tampa training facility has exceeded expectations in demand, and management anticipates continued growth in training activities, particularly with new product enhancements set to launch.

Market Positioning: The company is focused on leveraging its diverse product offerings to meet unmet needs in the market, which could enhance its competitive position. Overall, Tenon Medical demonstrated strong revenue growth and improved margins in Q2 2026, while also outlining strategic initiatives aimed at sustaining this momentum. However, ongoing operating losses and cash position concerns remain critical areas to monitor.